Cantor Fitzgerald Estimates Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Verastem in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the biopharmaceutical company will post earnings per share of ($3.24) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share.

Several other equities research analysts also recently weighed in on VSTM. Mizuho upped their target price on shares of Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. StockNews.com lowered Verastem from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Royal Bank of Canada lifted their target price on Verastem from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Verastem in a report on Thursday, December 19th. Finally, BTIG Research lifted their price objective on Verastem from $13.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.38.

Verastem Stock Up 1.3 %

Shares of NASDAQ:VSTM opened at $5.59 on Thursday. The firm has a market capitalization of $248.81 million, a PE ratio of -1.75 and a beta of 0.24. Verastem has a 1 year low of $2.10 and a 1 year high of $14.22. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.23 and a quick ratio of 3.23. The firm’s 50-day moving average is $4.91 and its two-hundred day moving average is $3.63.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.11.

Hedge Funds Weigh In On Verastem

Several hedge funds have recently made changes to their positions in VSTM. SG Americas Securities LLC grew its position in shares of Verastem by 152.8% during the fourth quarter. SG Americas Securities LLC now owns 36,515 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 22,071 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Verastem by 55.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 6,016 shares during the period. Barclays PLC grew its position in Verastem by 546.7% during the 3rd quarter. Barclays PLC now owns 55,708 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 47,094 shares during the last quarter. Geode Capital Management LLC increased its stake in Verastem by 67.6% in the third quarter. Geode Capital Management LLC now owns 890,599 shares of the biopharmaceutical company’s stock valued at $2,663,000 after purchasing an additional 359,060 shares during the period. Finally, XTX Topco Ltd acquired a new position in Verastem in the third quarter valued at $112,000. Hedge funds and other institutional investors own 88.37% of the company’s stock.

Insider Activity at Verastem

In related news, CEO Dan Paterson sold 8,568 shares of Verastem stock in a transaction on Monday, January 13th. The shares were sold at an average price of $5.24, for a total transaction of $44,896.32. Following the sale, the chief executive officer now directly owns 347,581 shares in the company, valued at $1,821,324.44. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 10,321 shares of company stock valued at $52,217 over the last three months. 2.20% of the stock is owned by corporate insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.